JAZZ vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 22, 2026

JAZZ

56.2
AI Score
VS
JAZZ Wins

MRNA

35.1
AI Score

Investment Advisor Scores

JAZZ

56score
Recommendation
HOLD

MRNA

35score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric JAZZ MRNA Winner
Revenue 2.28B 534.00M JAZZ
Net Income 485.90M -2.13B JAZZ
Net Margin 21.3% -397.9% JAZZ
Operating Income 584.80M -2.20B JAZZ
ROE 10.1% -31.4% JAZZ
ROA 4.4% -19.4% JAZZ
Total Assets 11.08B 10.96B JAZZ
Cash 1.62B 1.72B MRNA
Debt/Equity 0.91 0.09 MRNA
Current Ratio 1.78 2.29 MRNA
Free Cash Flow 786.10M -1.25B JAZZ

Relative Price Performance (Last 90 Days)

JAZZ 1M: -11.9% · 3M: -16.8% MRNA 1M: +34.6% · 3M: +331.1%

Current Technical Phase

JAZZ

Markdown
Sell / avoid

Price below a falling SMA50 (slope -4.6%), weak momentum, RSI 34

RSI (14): 33.7 · Price: $211.97

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (58.0% over 20 days), RSI 69

RSI (14): 69.1 · Price: $245.81

Fundamentals Snapshot

Metric JAZZ MRNA
Market Cap — —
Forward P/E 8.1 -51.1
Trailing P/E 14.7 —
Revenue (TTM) — —
Revenue Growth 0.2% 0.0%
Gross Margin 0.9% -0.7%
Operating Margin 0.3% -5.6%
EPS 14.59 -7.98
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, JAZZ is currently the stronger investment candidate, winning 8 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.